Daniel Halperin MD

PubMed

• Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues.
  Charles W Shi, Aagamjit Singh, Atulya A Khosla, Rohit Thummalapalli, Sarbajit Mukherjee
  European Journal of Cancer. 2026-10-05
• [Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2-3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-...
  Diego Ferone, Marianne Pavel, Ken Herrmann, Pamela L Kunz, Sten Myrehaug
  Eclinicalmedicine. 2026-08-01
• 1 citations
  Grade progression and high-grade transformation in neuroendocrine neoplasms.
  Udhayvir S Grewal, Matthew Gosse, Seth J Concors, Raul S Gonzalez, Po Hien Ear
  Endocrine-Related Cancer. 2026-07-01

Abstracts/Posters

• A prospective, multi-institutional phase II study pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumors.
  Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH, NANETS: North American Neuroendocrine Tumor Society Annual Meeting, Nashville, TN, USA, 10/6/2014
• Clinical Presentation and Outcomes in Patients with Advanced Pheochromcytoma/Paraganglioma: Evidence of Temozolomide Efficacy
  Halperin DM, Brais L, Ramaiya NH, Kulke MH, ASCO Annual Meeting, Chicago, IL, USA, 6/2014
• A phase I study of the anti-IGF-1R monoclonal antibody, IMC-A12, and everolimus in well-differentiated neuroendocrine tumors
  Dasari A, Phan AT, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F, Yao JC, ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA, 1/1/2014

Lectures

• A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). 
  ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020